AMENDMENTS TO THE CLAIMS

Claims 1-30 (canceled)

- 31. (New) Implant with a receiving space, a therapeutic agent contained therein, and an outlet element, wherein the outlet element has pores through which the therapeutic agent can leave the receiving space and be dispensed from the implant, wherein the therapeutic agent has or produces active substance molecules provided with a molecular envelope in order to influence the dispensing behavior.
- 32. (New) Implant per Claim 31, wherein the envelope consists at least essentially of surfactants.
- 33. (New) Implant per Claim 31, wherein the active substance molecules form micelles with the envelopes.
- 34. (New) Implant per Claim 31, wherein the size of the envelopes with the hydration shell amounts to at most $\frac{1}{5}$ of the pore diameter.
- 35. (New) Implant per Claim 31, wherein the outlet element is configured as a diffusion element with open pores with a pore size or pore wall that at least essentially only allows for a diffusion of the ensheathed active substance molecules through the diffusion element, without enabling a free flow through the outlet element.
- 36. (New) Implant per Claim 31, wherein the outlet element has open pores with pore walls that are chemically modified at least in regions, in order to interact with the ensheathed active substance molecules with regard to passage through the outlet element.
- 37. (New) Implant per Claim 31, wherein the implant has a solid reservoir containing the active substance molecules and surfactant(s).
- 38. (New) Implant per Claim 37, wherein the active substance molecules can dissolve to form micelles.

39. (New) Implant per Claim 37, wherein the molar ratio of the active substance molecules to the surfactants in the solid reservoir is at least 1:50.

40. (New) Therapeutic agent, wherein the therapeutic agent has or produces active substance molecules provided with molecular envelopes of surfactants.

41. (New) Therapeutic agent per Claim 40, wherein the therapeutic agent is an aqueous solution or a solid.

42. (New) Therapeutic agent per Claim 40, wherein the therapeutic agent is adapted for release through an implant of pores.

43. (New) Therapeutic agent per Claim 40, wherein the smallest, average, or largest diameter of the envelopes without the hydration shell is essentially 2 to 200 nm.

44. (New) Therapeutic agent per Claim 40, wherein the active substance molecules form micelles with the surfactants.

45. (New) Method for modification of the diffusion behavior of active substance molecules, wherein micelles are formed from surfactants and the active substance molecules, and the active substance molecules are ensheathed by the surfactants.

46. (New) Method per Claim 45, wherein the smallest, average, or largest diameter of the micelles without the hydration shell is at least essentially 2 to 200 nm.

47. (New) Method per Claim 45, wherein the micelles are released through an implant or pores.

48. (New) Micelle, comprising at least one active substance molecule, surrounded by an envelope formed from surfactant(s).

49. (New) Micelle per Claim 48, wherein the smallest, average, or largest diameter of the micelles without the hydration shell is at least essentially 2 to 200 nm.

50. (New) Micelle per Claim 48, wherein the micelles are essentially uniform in size or spherical in shape.